论文部分内容阅读
转移性肾细胞癌患者预后较差,多数患者在确诊后两年内死亡,仅有少部分病人延长生存期。回顾未经选择的病人总的反应率提示α-IFN作为一种活性剂在转移性肾细胞癌治疗中起重要作用。对49例转移性肾细胞癌病人进行了研究。用重组α-IFN与化疗进行治疗。除肉瘤样变异外,所有病人均经组织学证实为转移性肾细胞癌,包括肾细胞癌的所有组织亚型。研究对象分为两组:①已行肾切除术组;②原发肿瘤未切除组。每组作为单一研究并进行治疗及每个研究在达9人后被评价。对每组及全组进行统计学分析。已行肾切除的病人立即进行治疗。
Patients with metastatic renal cell carcinoma have a poor prognosis. Most patients die within two years after diagnosis, and only a few patients have prolonged survival. Reviewing the overall response rate of unselected patients suggests that α-IFN, as an active agent, plays an important role in the treatment of metastatic renal cell carcinoma. A total of 49 patients with metastatic renal cell carcinoma were studied. Treatment with recombinant alpha-IFN and chemotherapy. With the exception of sarcomatoid variants, all patients were histologically proven to be metastatic renal cell carcinomas, including all histologic subtypes of renal cell carcinoma. The subjects were divided into two groups: 1 had undergone nephrectomy; 2 had no resection of the primary tumor. Each group was treated as a single study and treated and each study was evaluated after reaching 9 people. Statistical analysis was performed on each group and whole group. Patients who have undergone nephrectomy are treated immediately.